Aurinia Pharmaceuticals Inc (AUPH)

[moosedogger]

How do you see AUPH in the next few months....

Caveat: Those toy "Magic 8 Balls" would likely substantially outperform my prowess for prognosticating. I recall the adage 'if you're going to predict, predict often'. I never get the memos announcing market tops and bottoms, but I'm fairly confident we're closer to the nadir than the zenith.

But since you asked, here's how I see The Good, The Bad And The Ugly re Aurinia:

It's good that the script numbers are improving, along with retention rates, etc.
It's good that AUPH has an FDA approved product for an underserved market and a decent cash cushion; a sharp contrast to many other bios.

It's bad that the XBI has really tanked badly over the past year, and recently hit a 5 year low.
The uncertainty created by Putin's invasion/war with Ukraine, the overall stock market collapse in many sectors, rising interest rates to fight the highest inflation in 40 years, the continuing COVID outbreaks, the political and economic divide in America, etc. are all contributing to negative market sentiment.

Since more than 120 biotechs are now trading at less than their cash value, I would guess the market would value AUR 200 & 300 at near zero.
I don't really know anything about them as they are such early development stage properties.

While it's good that 90% of lives in the USA are covered for Lupkynis, it's truly disappointing that so many rheumatologists and nephrologists seem to be amazingly ignorant of the vastly superior treatment qualities of Lupkynis and apparently instead prefer to start their patients on the garbage drug Benlysta.

I can't picture how these supposedly professional "doctors" could sleep at night if they knew the harm they are doing by ignoring/bypassing Lupkynis.

We have to hope that soon the Lupus Nephritis treatment guidelines are reviewed and rewritten so that Lupkynis is able to rightfully take it's place as the new SOC.

In short, I'm cautiously optimistic

cheers